Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

CYP2D6 Genotyping for Personalized Therapy of Tamoxifen in Indonesian Women with ER+ Breast Cancer

View ORCID ProfileBaitha Palanggatan Maggadani, Kathleen Irena Junusmin, Levana L. Sani, View ORCID ProfileCaroline Mahendra, Margareta Amelia, Gabriella, View ORCID ProfileAstrid Irwanto, Harmita, View ORCID ProfileYahdiana Harahap, Samuel J. Haryono
doi: https://doi.org/10.1101/2021.06.25.21259564
Baitha Palanggatan Maggadani
1Faculty of Pharmacy, University of Indonesia, Jakarta, Indonesia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Baitha Palanggatan Maggadani
Kathleen Irena Junusmin
2Nalagenetics Pte Ltd, Singapore, Singapore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Levana L. Sani
2Nalagenetics Pte Ltd, Singapore, Singapore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caroline Mahendra
2Nalagenetics Pte Ltd, Singapore, Singapore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Caroline Mahendra
Margareta Amelia
2Nalagenetics Pte Ltd, Singapore, Singapore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gabriella
2Nalagenetics Pte Ltd, Singapore, Singapore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Astrid Irwanto
2Nalagenetics Pte Ltd, Singapore, Singapore
3Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore, Singapore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Astrid Irwanto
Harmita
1Faculty of Pharmacy, University of Indonesia, Jakarta, Indonesia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yahdiana Harahap
1Faculty of Pharmacy, University of Indonesia, Jakarta, Indonesia
4Indonesia Defense University, Bogor, West Java, Indonesia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yahdiana Harahap
Samuel J. Haryono
4Indonesia Defense University, Bogor, West Java, Indonesia
5Surgical Oncology Division, SJH Initiative, MRCCC Siloam Hospital, Jakarta, Indonesia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: samuelharyono@yahoo.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Tamoxifen is a Selective Estrogen-Receptor Modulator (SERM) commonly prescribed for standard of care in estrogen receptor positive (ER+) breast cancer as an adjuvant therapy. Tamoxifen is metabolized by CYP2D6 into its active metabolite, endoxifen, which has been known to play an important role in reducing risk of ER+ breast cancer recurrence. CYP2D6 is a highly polymorphic gene with more than 100 alleles. The phenotype of this gene is categorized into ultrarapid metabolizer (UM), normal metabolizer (NM), intermediate metabolizer (IM), and poor metabolizer (PM). Certain CYP2D6 polymorphisms may cause reduced activity of this enzyme. Studies have found that reduced CYP2D6 activity in IM and PM patients causes low efficacy of standard tamoxifen therapy. This study aims to observe the distribution of CYP2D6 alleles and its correlation with endoxifen levels in Indonesian ER+ breast cancer patients. 151 patients who have received tamoxifen therapy for at least eight weeks were recruited prospectively. DNA and blood samples were collected with buccal swab and finger-prick methods, respectively. Genotyping was performed using the qPCR method while metabolite level measurement was performed using high performance liquid chromatography tandem mass spectrometry. We found that 40.67% of ER+ breast cancer patients recruited were IM. CYP2D6*10 was the most abundant allele (0.288) in this population, and *10/*36 was the most frequently observed diplotype (0.236). Endoxifen levels between the NM-PM, NM-IM, and IM-PM were statistically significant (p-value = 6.26 × 10−5, 9.12 × 10−5, and 4.714 × 10−3, respectively), and dose increase of tamoxifen to 40 mg daily successfully increased endoxifen levels in IMs to a similar level with NMs at baseline. Given these findings, implementing pharmacogenomic testing of CYP2D6 on ER+ breast cancer women who are about to undergo tamoxifen therapy may be beneficial to increase the likelihood of achieving expected endoxifen levels, thus better treatment efficacy.

Competing Interest Statement

KIJ, LLS, CM, MA, G, and AI are employees of Nalagenetics Pte Ltd, Singapore.

Clinical Trial

NCT04312347

Funding Statement

This research was funded by the University of Indonesia 2019-2020 research grant. Additional research expenses were also funded by Nalagenetics Pte Ltd, Singapore and PT Nalagenetik Riset Indonesia.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Institutional Review Board (IRB) approval was granted by MRCCC Siloam Hospitals Semanggi Ethics Review Committee (Jakarta, Indonesia) under IRB Reference Number 001/EA/KEPKK/RSMRCCC/V/2019.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The data that supports the findings of this study are available as supplementary materials. Any additional data is available from the corresponding author upon reasonable request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted June 30, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
CYP2D6 Genotyping for Personalized Therapy of Tamoxifen in Indonesian Women with ER+ Breast Cancer
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
CYP2D6 Genotyping for Personalized Therapy of Tamoxifen in Indonesian Women with ER+ Breast Cancer
Baitha Palanggatan Maggadani, Kathleen Irena Junusmin, Levana L. Sani, Caroline Mahendra, Margareta Amelia, Gabriella, Astrid Irwanto, Harmita, Yahdiana Harahap, Samuel J. Haryono
medRxiv 2021.06.25.21259564; doi: https://doi.org/10.1101/2021.06.25.21259564
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
CYP2D6 Genotyping for Personalized Therapy of Tamoxifen in Indonesian Women with ER+ Breast Cancer
Baitha Palanggatan Maggadani, Kathleen Irena Junusmin, Levana L. Sani, Caroline Mahendra, Margareta Amelia, Gabriella, Astrid Irwanto, Harmita, Yahdiana Harahap, Samuel J. Haryono
medRxiv 2021.06.25.21259564; doi: https://doi.org/10.1101/2021.06.25.21259564

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Pharmacology and Therapeutics
Subject Areas
All Articles
  • Addiction Medicine (238)
  • Allergy and Immunology (520)
  • Anesthesia (124)
  • Cardiovascular Medicine (1417)
  • Dentistry and Oral Medicine (217)
  • Dermatology (158)
  • Emergency Medicine (291)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (582)
  • Epidemiology (10280)
  • Forensic Medicine (6)
  • Gastroenterology (527)
  • Genetic and Genomic Medicine (2622)
  • Geriatric Medicine (254)
  • Health Economics (496)
  • Health Informatics (1728)
  • Health Policy (788)
  • Health Systems and Quality Improvement (671)
  • Hematology (266)
  • HIV/AIDS (564)
  • Infectious Diseases (except HIV/AIDS) (12080)
  • Intensive Care and Critical Care Medicine (647)
  • Medical Education (273)
  • Medical Ethics (83)
  • Nephrology (288)
  • Neurology (2453)
  • Nursing (144)
  • Nutrition (377)
  • Obstetrics and Gynecology (489)
  • Occupational and Environmental Health (566)
  • Oncology (1318)
  • Ophthalmology (400)
  • Orthopedics (145)
  • Otolaryngology (235)
  • Pain Medicine (168)
  • Palliative Medicine (51)
  • Pathology (342)
  • Pediatrics (776)
  • Pharmacology and Therapeutics (329)
  • Primary Care Research (296)
  • Psychiatry and Clinical Psychology (2393)
  • Public and Global Health (4996)
  • Radiology and Imaging (892)
  • Rehabilitation Medicine and Physical Therapy (523)
  • Respiratory Medicine (681)
  • Rheumatology (309)
  • Sexual and Reproductive Health (255)
  • Sports Medicine (244)
  • Surgery (297)
  • Toxicology (45)
  • Transplantation (140)
  • Urology (108)